QSAM Biosciences, Inc. General form of registration statement for all companies including face-amount certificate companies

PREFERRED STOCK, COMMON STOCK, AND WARRANTS (Tables)

12 Months Ended

Dec. 31, 2021

In 2021 and 2020, the Company issued 1,167,423 and 434,808 shares of common stock, respectively, as follows:


	For the Years Ended December 31,
	2021		2020
Conversion of bridge notes and accrued interest to common stock		165,692		332,804
Conversion of debentures and accrued expenses		15,825		5,467
Conversion of accrued salary and bonus, directors fees, and promissory notes with related parties		-		52,787
Conversion of Series A Stock to common stock		18,750		-
Conversion of Series B Stock to common stock		163,134		-
Exercise of Series B Warrants to common stock		46,786		-
Exchange of Series E-1 Stock to common stock		720,986		-
Stock based compensation for services		36,250		43,750
Total Common Shares issued		1,167,423		434,808

A summary of warrant activity and related information during the years ended December 31, 2021 and 2020 is as follows:

SCHEDULE OF WARRANT ACTIVITY

	Warrants		Weighted Average Exercise Price		Aggregate Intrinsic Value
Outstanding as of December 31, 2019		3,154	$	8.80	$	-
Issued		-		-		-
Exercised		-		-		-
Expired		2,000		-		-
Outstanding as of December 31, 2020		1,154	$	8.80	$	-
Issued		212,548		11.55		-
Exercised		46,786		10.00		-
Expired		129,832		9.82		-
Outstanding as of December 31, 2021		37,083	$	19.52	$	-

The following is a summary of the outstanding common stock warrants as of December 31, 2021:

	Number of Warrants		Exercise price per share		Expiration Date
Warrants issued in connection with issuance of Series B Stock to lead investor		11,875	$	10.00	January 15, 2022
Warrants issued in connection with convertible notes		25,208	$	24.00	October 31, 2022
Total Outstanding as of December 31, 2021		37,083